dr. saad on apalutamide combination for castration-resistant prostate cancer
Published 7 years ago • 797 plays • Length 1:47Download video MP4
Download video MP3
Similar videos
-
1:23
dr. saad on the safety profile of apalutamide in m0crpc
-
1:46
dr. saad on the clinical impact of apalutamide in nmcrpc
-
3:14
fred saad, md, details safety concerns when presenting apalutamide adt to nmcrpc patients
-
1:49
dr. saad on unanswered questions from the spartan trial in m0crpc
-
1:46
dr. agarwal on the qol with apalutamide in metastatic castration-sensitive prostate cancer
-
0:54
apalutamide combination is well tolerated in metastatic castration-sensitive prostate cancer
-
0:44
dr. wise on the fda approval of apalutamide in non-metastatic crpc
-
5:20
apalutamide in treating nonmetastatic crpc
-
4:36
nonmetastatic crpc: considerations for apalutamide
-
0:57
dr. morris on os data with apalutamide in prostate cancer
-
2:29
update: fda approves apalutamide (erleada) for metastatic castration-sensitive prostate cancer
-
4:53
apalutamide: a next-gen agent for nonmetastatic crpc
-
0:57
dr. agarwal on the tolerability of apalutamide in mcspc
-
4:56
fred saad, esmo 2022: phase iii propel trial of abiraterone olaparib in prostate cancer
-
1:06
dr. bradley on adverse events associated with enzalutamide and apalutamide in prostate cancer
-
2:50
live from asco: apalutamide for castration-sensitive prostate cancer
-
0:53
dr. freedland on real-world utility of enzalutamide in prostate cancer
-
5:59
apalutamide in combination with abiraterone acetate, docetaxel and prednisone for mcrpc
-
9:51
overall survival data presented at asco 2020 for nmcrpc